OR7A10 Boosts CAR-NK Therapy Effectiveness for Solid Tumors
Publication Title: OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours
Summary
- Question
- This study examined how engineering natural killer (NK) cells, a type of immune cell, with a specific receptor called OR7A10 could enhance their ability to fight solid tumors. The researchers aimed to address key challenges in chimeric antigen receptor (CAR)-NK cell therapy, such as poor tumor infiltration, limited persistence, and resistance within the tumor microenvironment.
- Why it Matters
- Solid tumors are difficult to treat because they create an environment that suppresses the immune system, making it challenging for therapies like CAR-NK cells to work effectively. CAR-NK therapy, which involves modifying NK cells to better recognize and attack cancer cells, has shown promise but remains limited by several obstacles. This research is significant because it identifies a potential way to overcome these challenges, offering a strategy to improve cancer treatment. If successful, it could lead to more effective, scalable therapies for patients with hard-to-treat solid tumors.
- Methods
- The researchers conducted an unbiased CRISPR activation screen, a technique used to turn on specific genes, in CAR-NK cells to identify targets that improve their effectiveness. They followed this with additional screening using barcoded genetic tools to validate their findings. They focused on OR7A10, a type of receptor found on cells, and engineered CAR-NK cells to include OR7A10 using a straightforward manufacturing method. The modified cells were then tested in multiple solid tumor models in mice.
- Key Findings
- The study found that CAR-NK cells engineered with OR7A10 showed enhanced performance in several key areas, including better proliferation (growth), activation, and resistance to the suppressive tumor environment. These modified cells were more effective at killing tumor cells and had improved persistence and metabolic fitness. In mouse models of solid tumors, these cells achieved complete tumor elimination in some cases, including a 100% complete response in a breast cancer model, along with long-term tumor control and improved survival.
- Implications
- These findings suggest that OR7A10-engineered CAR-NK cells could be a powerful new tool for treating solid tumors. The enhancements in tumor-killing ability and resistance to the suppressive environment of solid tumors make this approach a promising candidate for future clinical therapies. Additionally, the simple manufacturing process could make this therapy more accessible and scalable for widespread use.
- Next Steps
- The authors suggest further research to explore the clinical potential of OR7A10-engineered CAR-NK cells in human patients. They also propose investigating the use of this approach in additional types of solid tumors and refining the manufacturing process to optimize scalability and effectiveness.
- Funding Information
- This research was supported by the National Institutes of Health (NIH) and other funding sources as mentioned in the publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Yale University also provided funding and support for this research.
Full Citation
Yang L, Renauer PA, Tang K, Saskin J, Zhou L, Zou C, Lee SH, Fox M, Johnson-Noya S, Weiss B, Deng S, Fang P, Chen B, Sferruzza G, Fooladi S, Zhao K, Park D, Zhang F, Tu J, Chen J, Moliterno J, Gunel M, Peng L, Chen S. OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours. Nature 2026 DOI: 10.1038/s41586-026-10149-8.